|1.||Bierbower, Sonya M: 1 article (02/2015)|
|2.||Lechleiter, James D: 1 article (02/2015)|
|3.||Choveau, Frank S: 1 article (02/2015)|
|4.||Shapiro, Mark S: 1 article (02/2015)|
|5.||Li, Min: 1 article (05/2013)|
|6.||Zhou, Pingzheng: 1 article (05/2013)|
|7.||Gu, Min: 1 article (05/2013)|
|8.||Yu, Haibo: 1 article (05/2013)|
|9.||Gao, Zhaobing: 1 article (05/2013)|
|10.||Nan, Fa-jun: 1 article (05/2013)|
09/01/2002 - "These studies may help understand the pathophysiology of human epilepsies and represent the first step towards the discovery of new therapeutic targets, as exemplified in the case of the KCNQ potassium channels."
05/21/2013 - "Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels."
09/01/2008 - "As a result of genetic and functional investigations, not only will the pathophysiology of epilepsy be better understood, but newly discovered genes and pathophysiological pathways may also determine novel targets for pharmacotherapy, as has been shown for the anticonvulsant drug retigabine, which enhances the activity of neuronal KCNQ potassium channels."
|4.||Nervous System Diseases (Neurological Disorders)
|5.||Brain Injuries (Brain Injury)
|1.||D 23129 (retigabine)
|1.||Drug Therapy (Chemotherapy)